Egypt Diabetes Drugs and Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | > 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Egypt Diabetes Drugs and Devices Market Analysis
Egypt's diabetes drugs and devices market size is estimated at USD 0.7 billion in the current year. The market is expected to reach USD 0.9 billion in five years, registering a CAGR of more than 3.1% during the forecast period.
The COVID-19 pandemic positively impacted the growth of the diabetes care device market in Egypt. Patients having diabetes and infected with COVID-19 might suffer from high blood glucose, unusual variations in glucose levels, as well as diabetic issues. Diabetes among people with COVID-19 resulted in notable increases in severity and mortality regarding COVID-19 for those with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), mainly when linked to inadequate glycemic control. The growing awareness of the onset of hyperglycemia and new-onset diabetes (both T1DM and T2DM) in relation to COVID-19 and their associated worse outcomes has highlighted the need for regular monitoring and management of a patient's blood glucose. As such, a pandemic emergency has emphasized the importance of diabetes care devices through remote care.
Egypt is the ninth state regarding Diabetes prevalence globally. Currently, as specified by IDF, about 18. 4 % of the adult population in Egypt has diabetes. Over 11 % of the Egyptian population is diagnosed with Type-2 diabetes, as per Egypt's Adolescence Organization for Vitality Advancement. 73 million grown-ups (20-79) had diabetes in the IDF MENA location last year. This figure is estimated to boost to 95 million in seven years
Egypt has witnessed an alarming boost in the prevalence of diabetes; in recent years, the rate of diabetes is at an all-time high, mainly because of the way of life alterations. Diabetes is connected with a few vitality complications. Patients with diabetes demand a few daily corrections to maintain nominal blood glucose levels, such as administering extra insulin or ingesting different carbohydrates by observing their blood glucose levels. Diabetes poses an emerging medical care burden across the nation.
Thus, the above factors are expected to drive market growth over the forecast period.
Egypt Diabetes Drugs and Devices Market Trends
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
The continuous blood glucose monitoring segment is projected to grow at a CAGR of around 12% during the forecast period.
CGM is utilized by inserting a diminutive sensor into the abdomen or arm with a low plastic tube known as a cannula penetrating the top layer of skin. A sticky patch holds the sensor in place, letting it take glucose readings in interstitial fluid all day and night. Generally, the detectors need to be replaced in 7 to 14 days. A small, reusable transmitter associated with the sensor lets the scheme forward real-time readings wirelessly to a supervised contrivance that showcases blood glucose information. Several systems come with a committed monitor; several show the data via a smart device app.
Continual glucose observing detectors use glucose oxidase to find blood glucose levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, conveying an electrical sign to the transmitter. Sensors are one of the most significant components of continual glucose-observing gadgets. Technological advancements to enhance the precision of the detectors are expected to steer slice development during the forecast period.
The frequency of observing glucose levels depends on the write of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels regularly, supervise their blood glucose levels, and adjust the insulin dosing. The common CGM equipment displays an in-depth representation of blood glucose patterns and tendencies compared to daily tasks to check glucose levels at set periods. Furthermore, the common continual glucose observing equipment can retrospectively show the trends in blood glucose levels by downloading the information or giving a real-time characterization of glucose levels over handset showcases.
Rising diabetes prevalence
The main likelihood complied with amongst the Egyptian population is an unwholesome diet, sedentary way of life habits, and a family history of diabetes. The Egypt blood glucose observing industry grew to supervise glycosylated hemoglobin levels. Most diabetic patients in Egypt use blood glucose observing equipment to command blood glucose levels and their fluctuations. Thus, due to the elevated diabetes prevalence and technological adaptation, the industry is developing in Egypt.
In Egypt, the social level has a role in a critical part in patients' entry to vitality concern since the amount of health services centers, hospitals, and pharmacies is tiny in rural areas of interest compared with big cities and urban areas of interest. The financial level is a main determinant of people's entry to vitality care, as the salaries of most of Egypt's employees are insufficient to afford their monthly diabetes provides.
In Egypt, the social level has a role in a critical part in patients' entry to vitality concern since the amount of health services centers, hospitals, and pharmacies is tiny in rural areas of interest compared with big cities and urban areas of interest. The financial level is a main determinant of people's entry to vitality care, as the salaries of most of Egypt's employees are insufficient to afford their monthly diabetes provides. For students and school children with type 1 diabetes, the National Health Insurance System covers insulin, and the student pays nothing for NPH, mixed and short-acting insulins, and only 60% of the price of other types of insulin, which are usually unavailable in the pharmacies of the National Health Insurance System. However, the government is working in the direction of improving the access of patients through various initiatives.
Egypt Diabetes Drugs and Devices Industry Overview
Manufacturers are constantly innovating to survive in the market. Large companies like Abbott and Medtronic have made numerous mergers, acquisitions and partnerships to gain market dominance while adhering to organic growth strategies. The insulin-administration-device maker puts a lot of money into his RandD.
Egypt Diabetes Drugs and Devices Market Leaders
-
Medtronics
-
Roche
-
NovoNordisk
-
Sanofi
-
Omnipod
*Disclaimer: Major Players sorted in no particular order
Egypt Diabetes Drugs and Devices Market News
- October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.
- October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships align with the National Strategy for Industry and Advanced Technology and the ICV Program. It aims to attract investors and manufacturers to the UAE's pharmaceutical and medical equipment sectors. Under a separate MoU, PureHealth, and Gulf Pharmaceutical Industries Company will establish the first factory in the Middle East to produce Glargine to treat diabetes.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation (Market Size by Value - USD)
5.1 Devices
5.1.1 Monitoring Devices
5.1.1.1 Self-monitoring Blood Glucose Devices
5.1.1.2 Continuous Blood Glucose Monitoring
5.1.2 Management Devices
5.1.2.1 Insulin Pump
5.1.2.2 Insulin Syringes
5.1.2.3 Insulin Cartridges
5.1.2.4 Disposable Pens
5.2 Drugs
5.2.1 Oral Anti-Diabetes Drugs
5.2.2 Insulin Drugs
5.2.3 Combination Drugs
5.2.4 Non-Insulin Injectable Drugs
6. Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Medtronic
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
7.1.6 Novartis
7.1.7 Sanofi
7.1.8 Eli Lilly
7.1.9 Abbottt
7.1.10 Roche
7.1.11 Astrazeneca
7.1.12 Dexcom
7.1.13 Pfizer
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Egypt Diabetes Drugs and Devices Industry Segmentation
Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. to control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. many people with type 2 diabetes also need to take antidiabetic drugs. these drugs include diabetes medications and injections such as insulin. diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices ( management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). the report offers the value (in USD) and volume (in unit) for the above segments.
| Devices | ||||||
| ||||||
|
| Drugs | |
| Oral Anti-Diabetes Drugs | |
| Insulin Drugs | |
| Combination Drugs | |
| Non-Insulin Injectable Drugs |
Frequently Asked Questions
What is the current Egypt Diabetes Drugs and Devices Market size?
The Egypt Diabetes Drugs and Devices Market is projected to register a CAGR of greater than 3% during the forecast period (2024-2029)
Who are the key players in Egypt Diabetes Drugs and Devices Market?
Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Egypt Diabetes Drugs and Devices Market.
What years does this Egypt Diabetes Drugs and Devices Market cover?
The report covers the Egypt Diabetes Drugs and Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Egypt Diabetes Drugs and Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Egypt Diabetes Drugs and Devices Industry Report
Statistics for the 2024 Egypt Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Egypt Diabetes Drugs and Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
